SecBot SecBot
8-K ·Filed Nov 5, 2026

ONC

BeOne Medicines Ltd.
BULLISH
Impact 6/10
Horizonimmediate Processed11d 16h ago SEC0001628280-26-070469
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and accelerating BRUKINSA growth signal strong commercial momentum. Watch for the potential reversal of valuation allowances in Q4 2026, which could produce a material tax benefit. Also monitor upcoming ASH 2026 data readouts for BRUKINSA MANGROVE and tacabrutideg.

DirectionBullish
Confidencehigh
Horizonimmediate

Drugs in focus

ONC drug pipeline →

Ziihera

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).
Next catalyst
None dated

What to watchZiihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$387.25
T+0 close · Nov 5, 2026 · via day close
Latest settled
+7.41%
T+5 · $415.96
Vs SPY
+4.12%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $387.25entry
  2. T+1 · 11d ago +5.09%α +4.78% · $406.96
  3. T+5 · 5d ago +7.41%α +4.12% · $415.96
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BeOne Medicines reported Q3 2026 total revenue of $1.89B (+34% YoY) and GAAP diluted EPS of $3.28 (+201% YoY), both well above consensus estimates of $1.76B and $1.88. The company raised its full-year 2026 revenue guidance to $6.9B-$7.0B from $6.6B-$6.8B and lifted GAAP operating income guidance to $1.2B-$1.3B. BRUKINSA global sales reached $1.4B (+34% YoY), driven by U.S. growth of 36%.

Key Financial Metrics

EPS
$3.28
est $1.88 · +74.5%
Revenue
$1.9B
est $1.8B · +7.4% · +33.8% YoY
Rating
strong beat
Guidance
$6.9B-$7.0B
raised
Free Cash Flow
$473.5M
Gross Margin
88%

Key Facts

  • Total revenue $1.89B, +34% YoY, above $1.76B consensus
  • GAAP diluted EPS $3.28, +201% YoY, above $1.88 consensus
  • Non-GAAP diluted EPS $4.59, +73% YoY
  • BRUKINSA global sales $1.4B, +34% YoY; U.S. sales $1.0B, +36% YoY
  • Full-year 2026 revenue guidance raised to $6.9B-$7.0B from $6.6B-$6.8B
  • GAAP operating income guidance raised to $1.2B-$1.3B from $1.0B-$1.1B
  • GAAP net income $385M, +208% YoY
  • Free cash flow $474M, +34% YoY
  • Gross margin 88% GAAP, 90% adjusted, up from 86% prior year

Financial Impact

Revenue beat consensus by $130M (7.4%); EPS beat by $1.40 (74.5%); guidance raised by $300M at midpoint

revenueepsguidanceoperating incomefree cash flow

Segment Breakdown

SegmentRevenueGrowth
BRUKINSA$1.4B+34.0%
TEVIMBRA$243.0M+28.0%
Amgen in-licensed products$167.0M+26.0%

Risk Factors

  • R&D and SG&A expenses continue to grow (19% and 12% YoY respectively), pressuring margins
  • Non-cash intangible asset impairment of $22M from discontinuing POBEVCY promotion
  • Foreign exchange exposure; guidance assumes Nov 1, 2026 rates
  • Document contains text addressed to automated readers

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-070469
Document: bgne-20261105.htm0001628280-26-070469
Document: 0001628280-26-070469-index-headers.html0001628280-26-070469
Document: 0001628280-26-070469-index.html0001628280-26-070469
Document: 0001628280-26-070469.txt0001628280-26-070469
8-K Data (Synthetic)0001628280-26-070469

Track record

27 reports on ONC

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $411.29 −1.26% settles Nov 23
  2. Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
  3. Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
  6. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
  7. Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
  8. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
  9. Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (11h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026